Senior Director, Bacterial Vaccine Discovery
AstraZeneca
This listing was originally posted on AstraZeneca's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moAt AstraZeneca, we are pushing the boundaries of science to deliver life-changing medicines to patients facing the growing global threat of antimicrobial resistance (AMR) and serious bacterial infections. Our Early Infectious Disease (eID) team, based at our Gaithersburg, is a leading center for the discovery and development of novel biologics targeting bacterial and viral pathogens.
We are seeking a Senior Director, Bacterial Vaccine Discovery to lead the bacterial vaccines pillar within our Bacterial mAbs and Vaccines Team. This senior scientific leader will define and deliver the discovery strategy for novel bacterial vaccines — spanning carbohydrate conjugate, mRNA, and protein-based approaches — lead a multidisciplinary team, and partner closely with other leaders on the team.
Accountabilites:
Required Skills:
·
Date Posted
20-Oct-2026Closing Date
25-Oct-2026Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at AstraZeneca?
Help others prepare — share your experience anonymously.
PHARMACEUTICAL
Small Molecules, Vaccines, Biologics
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo